Akebia Therapeutics, Inc. Stock Analysis & AI Score
Akebia Therapeutics, Inc. (AKBA) has an ST Score of 33.3 (C-), driven by its Profitability (B) and held back by its Financial Strength (D-). Analysts rate it Buy with a $1.00 price target (+8.8% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Akebia Therapeutics, Inc. (AKBA) has an ST Score of 33.3 (C-), driven by its Profitability (B) and held back by its Financial Strength (D-). Analysts rate it Buy with a $1.00 price target (+8.8% upside).
- Strongest
- ProfitabilityB
- Weakest
- Financial StrengthD-
All factor grades
- ProfitabilityB
- MomentumC
- ValuationC-
- GrowthC-
- ForecastC-
- Financial StrengthD-
- Piotroski3/9
Contact
AKBA stock: frequently asked questions
What is AKBA's ST Score?
Akebia Therapeutics, Inc. (AKBA) has an ST Score of 33.3 (C-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is AKBA a buy, hold, or sell?
Analysts rate AKBA a Buy, with a price target of $1.00 (+8.8% vs the current price). Our ST Score grades it C- (33.3/100). The ST Score is a data-driven signal, not a recommendation.
What are AKBA's factor grades?
Valuation C-, Profitability B, Financial Strength D-, Momentum C, Growth C-, Forecast C-.
What is AKBA's valuation grade?
Akebia Therapeutics, Inc. (AKBA) earns a valuation grade of C-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is AKBA's growth grade?
Akebia Therapeutics, Inc. (AKBA) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is AKBA's profitability grade?
Akebia Therapeutics, Inc. (AKBA) earns a profitability grade of B, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is AKBA's financial strength grade?
Akebia Therapeutics, Inc. (AKBA) earns a financial strength grade of D-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for AKBA?
The average analyst price target for Akebia Therapeutics, Inc. (AKBA) is $1.00 from 12 analysts, which is +8.8% versus the recent price of $0.92.
What is AKBA's Piotroski score?
Akebia Therapeutics, Inc. (AKBA) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.